Irradiation in Paediatrics: Neurocognition, Neuroimaging and Evaluation of Memory and Attention

This is a prospective, open-label, multicentric study designed to correlate the dose delivered to the hippocampus with declarative memory deficits 2 years after radiotherapy treatment in a paediatric population who had received brain irradiation between the ages of 4 and 12 for a brain tumour. In order to meet this objective, several neuropsychological assessments consisting of parental questionnaires and cognitive tests will be carried out during the course of the study, at the following two stages: * A 1st assessment at patient inclusion, i.e. 2 years after the end of radiotherapy treatmen

Trial Details

NCT ID
NCT06599879
Phase
NA
Sponsor
Institut Claudius Regaud
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • Neuropsychological assessments:
Locations (sample)
  • Angers, France|47.47156,-0.55202
  • Bordeaux, France|44.84124,-0.58046
  • Caen, France|49.18585,-0.35912
  • Dijon, France|47.31344,5.01391
  • Lille, France|50.63391,3.05512

Key Eligibility Criteria

  • Patient who has received localised brain irradiation or craniospinal irradiation for a brain tumour whose treatment includes first-line radiotherapy.
  • Patient with one of the following tumour types: ependymomas, medulloblastomas, malignant germ cell tumours, craniopharyngioma, pinealoblastoma.
  • Patient aged between 4 and 12 years at the time of radiotherapy treatment.
  • End of irradiation within 2 years (+/-3 months) prior to inclusion.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →